KRAS and non-small cell lung carcinoma: Using both pharmacological inhibition with SGI-7079 and genetic suppression with siRNA, we demonstrated that AXL inhibition significantly sensitizes KRAS mutant NSCLC cell lines, such as A549 (KRAS G12S) and H460 (KRAS Q61H), to Dasatinib.